/ /

  • linkedin
  • Increase Font
  • Sharebar

    Encouraging results for device to treat wAMD

    Long-term positive outcomes of a minimally invasive retrobulbar episcleral brachytherapy device (SalutarisMD, Salutaris Medical Devices, London, UK) show promise for treating wet age-related macular degeneration (wAMD), according to data presented at the RCO congress.

    The results, presented by Mr Kamaljit Balaggan from Moorfields Eye Hospital NHS Foundation Trust in London, UK, outlined the feasibility and tolerability of the SalutarisMD investigational treatment for wAMD using a single dose of episcleral brachytherapy in combination with intraocular anti-VEGF injections. The study included six patients, who all experienced increases in BCVA after 3 months. After a year, all patients had a reduced macular thickness and three continued to demonstrate improved BCVA. Additionally, two patients did not require any further anti-VEGF injections during follow up.

    These long-term results demonstrate promise for this device in the treatment of wAMD. Dr Laurence Marsteller, managing director of SalutarisMD, asserted, “Our hope is that this technology will ultimately improve the lives of those suffering from this debilitating disease.”

    More information about this technology and the study may be found on the company's website here.

    New Call-to-action


    View Results